gdc
FDA Approvals, News & UpdatesLymphoma

Tecartus First Gene Therapy FDA Approved for Patients with Mantle-Cell Lymphoma

The FDA approved Tecartus as the first gene therapy (or CAR T-cell therapy) for patients with mantle-cell lymphoma, a rare type of non-Hodgkin lymphoma, that progressed after previous therapies.
October 2020 Vol 6 No 5

In July 2020, the FDA approved Tecartus (brexucabtagene autoleucel; from Kite Pharma), a CAR T-cell therapy, for the treatment of adults with mantle-cell lymphoma whose disease has not responded to or has relapsed after other therapies. Tecartus is the first gene therapy approved by the FDA specifically for the treatment of patients with mantle-cell lymphoma, a rare type of B-cell non-Hodgkin’s lymphoma.

Commenting on this FDA approval, Peter Marks, MD, PhD, Director of the FDA’s Center for Biologics Evaluation and Research, said, “This approval is yet another example of customized treatments that use a patient’s own immune system to help fight cancer, while using a scientific advance in this promising new area of medicine. We’re seeing continued advances in the field of gene therapy and remain committed to supporting innovation in this promising new area of medicine.”

The FDA approved Tecartus based on results from a multicenter clinical trial of 60 adults with relapsed or refractory mantle-cell lymphoma who were followed for 6 months or longer after their first response to treatment. Overall, 87% of the patients had a response to therapy with Tecartus, including 62% of patients who reached remission (no cancer).

Like all gene therapies, Tecartus is made from the patient’s own immune system by collecting the patient’s cells and genetically modifying them to target the lymphoma cells. These modified T-cells are then infused back into the patient.

The most common side effects reported with Tecartus were serious infections, low blood cell counts, and a weakened immune system. Side effects usually appear within the first 1 to 2 weeks after treatment, but some adverse reactions may occur later. Of note, Tecartus can lead to cytokine release syndrome, a life-threatening condition.

Share this:

Recommended For You
FDA Approvals, News & UpdatesMultiple Myeloma
Blenrep Approved for the Treatment of Relapsed or Refractory Multiple Myeloma
Adrug called Blenrep (belantamab mafodotin-blmf) was recently approved by the Food and Drug Administration (FDA) for adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies (including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent).
FDA Approvals, News & UpdatesLeukemia
Imbruvica/Rituximab Combo Approved for First-Line Leukemia
The Food and Drug Administration (FDA) has expanded the use of the anticancer drug Imbruvica (ibrutinib) to be used in combination with rituximab for the treatment of the most common type of leukemia in adults, chronic lymphocytic leukemia (CLL), or its variant called small lymphocytic lymphoma (SLL).
Last modified: November 24, 2020

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country